Oncotarget | Oncogenic driver FGFR3-TACC3 requires 5 coiled-coil heptads for activation and disulfide bonds for stability
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.